Liver enzyme elevation in hepatitis C virus (HCV) - HIV-coinfected patients prior to and after initiating HAART

Role of HCV genotypes

Ivana Maida, Sergio Babudieri, Cinzia Selva, Gianpiero D'Offizi, Luisa Fenu, Giuliana Solinas, Pasqualino Narciso, Maria Stella Mura, Marina Núnez

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Transaminase elevation is frequently seen in hepatitis C virus (HCV)-HIV-coinfected patients receiving antiretroviral therapy (ART), representing an increase in the immune response against HCV and being one of the mechanisms proposed to be involved. There is a report claiming that HCV genotype 3 is an independent risk factor. Our objectives were to assess the incidence of liver toxicity in an HIV-HCV-coinfected population with relatively preserved cellular immunity, and the role of HCV genotypes in the elevation of liver enzymes, both at baseline and after initiating ART. All HIV + patients with positive anti-HCV serology and CD4 + cell counts above 100/mm 3 who began triple ART were identified, and their HCV-RNA levels and HCV genotype were determined. Liver enzymes were determined at baseline and bimonthly during follow-up. Of anti-HCV patients 147 were included, 128 (87.1%) of whom had detectable plasma HCV-RNA. HCV-1 and HCV-4 genotypes were found to confer an increased probability of having at baseline transaminases within normal limits over the other genotypes. Severe transaminase elevations (grades 3 and 4) occurred in 5/124 patients (4.0%), all with high pre-HAART ALT and positive HCV-RNA levels. Multivariate analysis showed that patients with genotype HCV-3 had a 3.27 times higher risk of developing HAART-related transaminase elevations of any grade. In conclusion, subjects with the HCV-1 genotype more often had transaminases within normal limits at baseline. The incidence of severe transaminase elevation after initiating ART was very low (4%) in this HIV + population with relatively preserved cellular immunity. HCV genotype 3 was identified as a risk factor for the development of transaminase elevation of any grade.

Original languageEnglish
Pages (from-to)139-143
Number of pages5
JournalAIDS Research and Human Retroviruses
Volume22
Issue number2
DOIs
Publication statusPublished - Feb 2006

Fingerprint

Highly Active Antiretroviral Therapy
Hepacivirus
Genotype
HIV
Liver
Enzymes
Transaminases
RNA
Cellular Immunity
Incidence
Serology
Therapeutics
CD4 Lymphocyte Count
Population

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Liver enzyme elevation in hepatitis C virus (HCV) - HIV-coinfected patients prior to and after initiating HAART : Role of HCV genotypes. / Maida, Ivana; Babudieri, Sergio; Selva, Cinzia; D'Offizi, Gianpiero; Fenu, Luisa; Solinas, Giuliana; Narciso, Pasqualino; Mura, Maria Stella; Núnez, Marina.

In: AIDS Research and Human Retroviruses, Vol. 22, No. 2, 02.2006, p. 139-143.

Research output: Contribution to journalArticle

Maida, Ivana ; Babudieri, Sergio ; Selva, Cinzia ; D'Offizi, Gianpiero ; Fenu, Luisa ; Solinas, Giuliana ; Narciso, Pasqualino ; Mura, Maria Stella ; Núnez, Marina. / Liver enzyme elevation in hepatitis C virus (HCV) - HIV-coinfected patients prior to and after initiating HAART : Role of HCV genotypes. In: AIDS Research and Human Retroviruses. 2006 ; Vol. 22, No. 2. pp. 139-143.
@article{d099dd1ee85a42c6b23471974428bbdb,
title = "Liver enzyme elevation in hepatitis C virus (HCV) - HIV-coinfected patients prior to and after initiating HAART: Role of HCV genotypes",
abstract = "Transaminase elevation is frequently seen in hepatitis C virus (HCV)-HIV-coinfected patients receiving antiretroviral therapy (ART), representing an increase in the immune response against HCV and being one of the mechanisms proposed to be involved. There is a report claiming that HCV genotype 3 is an independent risk factor. Our objectives were to assess the incidence of liver toxicity in an HIV-HCV-coinfected population with relatively preserved cellular immunity, and the role of HCV genotypes in the elevation of liver enzymes, both at baseline and after initiating ART. All HIV + patients with positive anti-HCV serology and CD4 + cell counts above 100/mm 3 who began triple ART were identified, and their HCV-RNA levels and HCV genotype were determined. Liver enzymes were determined at baseline and bimonthly during follow-up. Of anti-HCV patients 147 were included, 128 (87.1{\%}) of whom had detectable plasma HCV-RNA. HCV-1 and HCV-4 genotypes were found to confer an increased probability of having at baseline transaminases within normal limits over the other genotypes. Severe transaminase elevations (grades 3 and 4) occurred in 5/124 patients (4.0{\%}), all with high pre-HAART ALT and positive HCV-RNA levels. Multivariate analysis showed that patients with genotype HCV-3 had a 3.27 times higher risk of developing HAART-related transaminase elevations of any grade. In conclusion, subjects with the HCV-1 genotype more often had transaminases within normal limits at baseline. The incidence of severe transaminase elevation after initiating ART was very low (4{\%}) in this HIV + population with relatively preserved cellular immunity. HCV genotype 3 was identified as a risk factor for the development of transaminase elevation of any grade.",
author = "Ivana Maida and Sergio Babudieri and Cinzia Selva and Gianpiero D'Offizi and Luisa Fenu and Giuliana Solinas and Pasqualino Narciso and Mura, {Maria Stella} and Marina N{\'u}nez",
year = "2006",
month = "2",
doi = "10.1089/aid.2006.22.139",
language = "English",
volume = "22",
pages = "139--143",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Liver enzyme elevation in hepatitis C virus (HCV) - HIV-coinfected patients prior to and after initiating HAART

T2 - Role of HCV genotypes

AU - Maida, Ivana

AU - Babudieri, Sergio

AU - Selva, Cinzia

AU - D'Offizi, Gianpiero

AU - Fenu, Luisa

AU - Solinas, Giuliana

AU - Narciso, Pasqualino

AU - Mura, Maria Stella

AU - Núnez, Marina

PY - 2006/2

Y1 - 2006/2

N2 - Transaminase elevation is frequently seen in hepatitis C virus (HCV)-HIV-coinfected patients receiving antiretroviral therapy (ART), representing an increase in the immune response against HCV and being one of the mechanisms proposed to be involved. There is a report claiming that HCV genotype 3 is an independent risk factor. Our objectives were to assess the incidence of liver toxicity in an HIV-HCV-coinfected population with relatively preserved cellular immunity, and the role of HCV genotypes in the elevation of liver enzymes, both at baseline and after initiating ART. All HIV + patients with positive anti-HCV serology and CD4 + cell counts above 100/mm 3 who began triple ART were identified, and their HCV-RNA levels and HCV genotype were determined. Liver enzymes were determined at baseline and bimonthly during follow-up. Of anti-HCV patients 147 were included, 128 (87.1%) of whom had detectable plasma HCV-RNA. HCV-1 and HCV-4 genotypes were found to confer an increased probability of having at baseline transaminases within normal limits over the other genotypes. Severe transaminase elevations (grades 3 and 4) occurred in 5/124 patients (4.0%), all with high pre-HAART ALT and positive HCV-RNA levels. Multivariate analysis showed that patients with genotype HCV-3 had a 3.27 times higher risk of developing HAART-related transaminase elevations of any grade. In conclusion, subjects with the HCV-1 genotype more often had transaminases within normal limits at baseline. The incidence of severe transaminase elevation after initiating ART was very low (4%) in this HIV + population with relatively preserved cellular immunity. HCV genotype 3 was identified as a risk factor for the development of transaminase elevation of any grade.

AB - Transaminase elevation is frequently seen in hepatitis C virus (HCV)-HIV-coinfected patients receiving antiretroviral therapy (ART), representing an increase in the immune response against HCV and being one of the mechanisms proposed to be involved. There is a report claiming that HCV genotype 3 is an independent risk factor. Our objectives were to assess the incidence of liver toxicity in an HIV-HCV-coinfected population with relatively preserved cellular immunity, and the role of HCV genotypes in the elevation of liver enzymes, both at baseline and after initiating ART. All HIV + patients with positive anti-HCV serology and CD4 + cell counts above 100/mm 3 who began triple ART were identified, and their HCV-RNA levels and HCV genotype were determined. Liver enzymes were determined at baseline and bimonthly during follow-up. Of anti-HCV patients 147 were included, 128 (87.1%) of whom had detectable plasma HCV-RNA. HCV-1 and HCV-4 genotypes were found to confer an increased probability of having at baseline transaminases within normal limits over the other genotypes. Severe transaminase elevations (grades 3 and 4) occurred in 5/124 patients (4.0%), all with high pre-HAART ALT and positive HCV-RNA levels. Multivariate analysis showed that patients with genotype HCV-3 had a 3.27 times higher risk of developing HAART-related transaminase elevations of any grade. In conclusion, subjects with the HCV-1 genotype more often had transaminases within normal limits at baseline. The incidence of severe transaminase elevation after initiating ART was very low (4%) in this HIV + population with relatively preserved cellular immunity. HCV genotype 3 was identified as a risk factor for the development of transaminase elevation of any grade.

UR - http://www.scopus.com/inward/record.url?scp=33244484852&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33244484852&partnerID=8YFLogxK

U2 - 10.1089/aid.2006.22.139

DO - 10.1089/aid.2006.22.139

M3 - Article

VL - 22

SP - 139

EP - 143

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 2

ER -